Welcome to our dedicated page for Senseonics Holdings SEC filings (Ticker: SENS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Senseonics Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Senseonics Holdings's regulatory disclosures and financial reporting.
Senseonics Holdings, Inc. has completed the previously announced local asset purchase agreements with Ascensia Diabetes Care for its commercial Eversense continuous glucose monitoring (CGM) activities in several European markets. These transactions cover Eversense CGM commercial assets in Germany, Spain, Sweden and Italy.
The asset purchases in Germany, Spain and Sweden closed on June 1, 2026, and the purchase related to Italy closed on June 8, 2026, with the transfer effective for finance and accounting purposes as of June 1, 2026. This shifts ownership of these commercial assets from Ascensia to Senseonics and its affiliates in the covered countries.
Senseonics Holdings, Inc. reported that Chief Medical Officer Francine Kaufman received equity-based compensation on May 19, 2026. She was granted 63,177 restricted stock units, each representing a contingent right to one share of common stock. Following this grant, she holds 181,067 common shares directly.
She was also awarded an employee stock option for 86,935 shares of common stock at an exercise price of $5.54 per share, expiring on May 18, 2036. The RSUs vest in eight equal installments beginning June 15, 2026, while the options vest in 48 equal monthly installments starting May 19, 2026, in each case subject to her continued service.
Senseonics Holdings, Inc. reported that GC & Corp. Development Advisor Kenneth L. Horton received equity awards as part of his compensation. He was granted 157,943 restricted stock units (RSUs), each representing a right to receive one share of common stock. These RSUs vest in eight equal installments, starting on June 15, 2026, with the remaining seven installments vesting every six months beginning November 15, 2026, contingent on his continuous service.
Horton was also granted 217,338 employee stock options to buy common stock at an exercise price of $5.54 per share, expiring on May 18, 2036. These options vest in 48 equal monthly installments beginning on May 19, 2026, also subject to continued service. After these awards, he directly holds 295,057 shares of common stock and 217,338 options.
Senseonics Holdings, Inc. Chief Operating Officer Mukul Jain reported equity awards consisting of restricted stock units and stock options. He received 270,759 RSUs, each representing one share of common stock, and 372,579 employee stock options with an exercise price of $5.54 per share.
The RSUs vest in eight equal installments, starting on June 15, 2026, then every six months beginning November 15, 2026, subject to his continued service. The options vest in 48 equal monthly installments beginning May 19, 2026 and expire on May 18, 2036, also contingent on continued service. After the RSU grant, Jain directly holds 517,057 shares of common stock.
Senseonics Holdings director Stephen P. DeFalco received new equity awards. He was granted 9,852 shares of common stock as a restricted stock unit award with no cash paid per share. Following this grant, he directly holds 111,019 common shares.
He was also granted stock options covering 13,574 shares of common stock at an exercise price of $5.71 per share, expiring on May 19, 2036. Both the RSUs and options vest in full on the earlier of the one-year anniversary of the grant date or the next annual stockholders meeting, subject to his continuous service. The reported numbers reflect a prior 1-for-20 reverse stock split effective October 17, 2025.
Senseonics Holdings, Inc. director Steven Edelman received equity compensation on a grant date of May 20, 2026. He was awarded 9,852 shares of common stock in the form of restricted stock units under the company’s non-employee director compensation policy. These RSUs vest in full on the earlier of one year from grant or the next annual stockholders meeting, provided he remains in continuous service, and each RSU converts into one share of common stock. He was also granted stock options for 13,574 shares of common stock at an exercise price of $5.71 per share, vesting on the same schedule and expiring on May 19, 2036. Following the RSU grant, he directly holds 88,681 shares of common stock.
Senseonics Holdings director Edward Fiorentino received new equity awards as part of the company’s non-employee director compensation policy. He was granted 9,852 restricted stock units, each representing a contingent right to one share of common stock, vesting in full on the earlier of the one-year anniversary of the grant date or the next annual stockholders meeting, subject to his continuous service. He also received a stock option covering 13,574 shares of common stock at an exercise price of $5.71 per share, with the same vesting schedule. Following these awards, Fiorentino directly holds 83,339 shares of common stock and 13,574 stock options.
Senseonics Holdings director Sharon Larkin received new equity awards as part of the company’s non-employee director compensation policy. She was granted 9,852 restricted stock units, each representing one share of common stock, and 13,574 stock options with an exercise price of $5.71 per share expiring on May 19, 2036. The RSUs and options vest in full on the earlier of one year from grant or the next annual stockholders meeting, subject to her continuous service. Following the stock award, she directly holds 41,862 shares of common stock.
Senseonics Holdings, Inc. director Douglas S. Prince received equity compensation in the form of restricted stock units and stock options. He was granted 9,852 RSUs, each representing one share of common stock, and a stock option for 13,574 shares at an exercise price of $5.71 per share.
The RSUs and options were granted under the company’s non-employee director compensation policy and vest in full on the earlier of one year from grant or the next annual stockholders meeting, subject to his continuous service. Following these awards, he directly holds 67,816 shares of common stock and 13,574 options.
Senseonics Holdings, Inc. director Douglas A. Roeder reported equity compensation grants consisting of restricted stock units and stock options. He received 9,852 RSUs, each representing one share of common stock, and a stock option for 13,574 shares at an exercise price of $5.7100 per share. Both awards vest in full on the earlier of the one-year anniversary of the grant date or the next annual stockholders meeting, subject to his continuous service. Following the RSU grant, Roeder directly holds 154,487 shares of common stock, and the new option award expires on May 19, 2036.